The Anti-Mullerian hormone as a predictor of intra-cytoplasmic sperm injection outcome in patients with polycystic ovary syndrome

Abstract

Polycystic ovary syndrome is the most common cause of oligo-ovulation and anovulation both in the general population and among women presenting with infertility. Polycystic ovary syndrome is a complex and heterogeneous disorder. Being a common endocrine disorder affecting women in reproductive age, a multifaceted reproductive, cosmetic and metabolic problems, with mysterious pathophysiological and molecular basis it represents a challenge for clinical investigators. The diagnosis of PCOS remains controversial and is based on various signs, symptoms, and/or laboratory findings that are not universally accepted. The diagnostic criteria of the syndrome were revised by the Rotterdam European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine Sponsored PCOS Consensus Workshop Group in 2003 where the following criteria were established: oligoamenorrhea, clinical and biochemical signs of hyperandrogenism, and echographically confirmed polycystic ovary. Two of the three criteria are required for diagnosis.